ProAgio - ProDa BioTech
Alternative Names: ACT-50Latest Information Update: 18 Jun 2024
At a glance
- Originator Georgia State University
- Developer Georgia State University; ProDa BioTech
- Class Antineoplastics; Proteins
- Mechanism of Action Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pancreatic cancer; Solid tumours
Most Recent Events
- 14 Jun 2024 ProDa Biotech plans a phase I/II trial for Triple-negative Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV, Injection) (NCT06460298)
- 29 Dec 2023 ProDa BioTech in collaboration with Georgia State University and University of Alabama plans a phase I/Ib trial for Pancreatic cancer (Metastatic disease, Late-stage disease, Combination therapy, First-line therapy) (IV) (NCT06182072)
- 11 Oct 2023 Efficacy, pharmacokinetics and adverse events data from phase I trial in Solid tumours and Pancreatic cancer were presented at the International Conference on Molecular Targets and Cancer Therapeutics ( AACR-NCI-EORTC 2023)